Pneumococcal Vaccine Schedules
Phase 4
Recruiting
- Conditions
- pneumococci
- Registration Number
- PACTR202105646878477
- Lead Sponsor
- ondon School of Hygiene and Tropical Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 40000
Inclusion Criteria
Resident in the study area
Exclusion Criteria
Intent to move out of the study area before 4 months of age.
Age greater than 9 months
Completed PCV schedule
Contraindication to PCV13 – severe hypersensitivity to a previous dose of PCV13
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method asopharyngeal (NP) carriage of vaccine-type (VT) pneumococci in children aged 2 weeks - 59 months with clinical pneumonia.
- Secondary Outcome Measures
Name Time Method .NP carriage of non-vaccine-type (NVT) pneumococci in children aged 2 weeks - 59 months with clinical pneumonia.<br>• Population-based NP prevalence of VT and NVT pneumococci with measurement of interpersonal contact patterns.<br>• NP prevalence of VT and NVT pneumococci in infants presenting for the first dose of PCV aged 6 – 12 weeks.<br>• Incidence of radiological pneumonia in children aged 2 weeks - 59 months.<br>• Incidence of clinical pneumonia in children aged 2 weeks - 59 months.<br>• Incidence of clinical pneumonia with NP carriage of VT pneumococci in children aged 2 weeks – 59 months<br>• Incidence of serotype-specific IPD in children aged 2 weeks - 59 months.<br>• Incidence of hospitalisation in children aged 2 weeks – 59 months.<br>• Mortality in children aged 2 weeks - 59 months.<br>